Factors Associated with Severity of Alopecia Areata

Hye Rin You, Seong-Jin Kim

Department of Dermatology, Chonnam National University Medical School, Gwangju, Korea

Background: Alopecia areata is the most common cause of localized, nonscarring alopecia. Unfortunately, there are few data regarding clinical features and epidemiology of alopecia areata in Korean patients, and its clinical course and treatment response rates are unpredictable. Objective: This study strived to investigate the differences in clinical profiles according to disease severity and to determine risk factors for severe alopecia areata. Methods: A total of 1,137 patients from 2006 to 2015 were analyzed retrospectively. Patients were subdivided into two groups: mild-to-moderate and severe alopecia areata. The groups were compared on the basis of age of onset, duration, sex, family history, comorbid disorders including autoimmune diseases, nail changes, and laboratory test results. Results: Eight hundred eighty-three patients were in the mild-to-moderate alopecia areata group and 254 patients were in the severe group. Average onset age was 30.77 ± 17.66 years and 30.60 ± 16.75 years in the mild-to-moderate and severe groups, respectively. Disease duration was statistically longer in the severe group. Male sex, nail changes, and thyroid diseases were more common in the severe group. Hypertension, diabetes mellitus, dyslipidemia, atopic dermatitis, and family history did not differ between groups. Of the serologic values, only alkaline phosphatase was considerably differing between groups. Male sex, presence of nail changes, and disease duration greater than one year were identified as significant risk factors for severe alopecia areata. Conclusion: This is the largest case analysis in Korean patients with alopecia areata. Clinical profiles stratified by disease severity warrant further study. (Ann Dermatol 29(5) 565 ~ 570, 2017)

Keywords- Alopecia, Alopecia areata, Alopecia universalis, Epidemiology, Risk factors

INTRODUCTION

Alopecia areata (AA) is a common disease that directly relates to nonscarring hair loss. The typical clinical aspects are variable sized, well-circumscribed, oval or round bald patches. In most cases, spontaneous regrowth of hair occurs and the treatment response is good. However, some patients show chronicity and rapid progression, resulting in the entire loss of scalp and body hair. As the course of the disease is variable, it is very difficult to predict the prognosis and treatment response on clinical examination. The exact pathogenesis remains unclear, but it is assumed that AA is an organ-specific autoimmune disease, mediated by autoreactive CD8+ T cells, which affects hair follicles. Consequently, atopic dermatitis, autoimmune diseases including vitiligo, and thyroid disease are associated with AA. Reports on serologic findings are diverse, but patients with AA tend to show autoantibodies at a higher rate than the general population. There are few reports concerning the clinical characteristics, epidemiology, and prognosis of Korean patients with AA. Therefore, we investigated the differences in clinical profiles based on disease severity that have relevance to prognosis and risk for severe AA.
# MATERIALS AND METHODS

## Patient population

All subjects with AA who were examined at Chonnam National University Hospital (Gwangju, Korea) from January 2006 to December 2015 were enrolled in this study. The study protocol was approved by the institutional review board of Chonnam National University Hospital (IRB no. CNUH 2017-259).

## Methods

This study retrospectively analyzed the medical records and clinical photographs. Patients were divided into two groups based on the extent of AA at their first medical examination: less than 50% involvement of the entire scalp was considered mild-to-moderate AA, and greater than 50% involvement of the entire scalp, alopecia totalis, and alopecia universalis were considered severe AA. Patients with acute diffuse and total alopecia or rapidly progressive AA were identified based on clinical history and disease progression, and were excluded from the analysis. Demographic data on age, sex, duration, age of onset, family history, nail changes, and associated diagnoses including autoimmune diseases were obtained for all patients. We investigated the presence of thyroid diseases including thyroid cancer, Grave’s disease, Hashimoto thyroiditis, simple goiter, and autoimmune diseases including autoimmune thyroid disease (Grave’s disease, Hashimoto thyroiditis), systemic lupus erythematosus, vitiligo, rheumatoid arthritis, adult-onset Still’s disease, ulcerative colitis, Sjogren’s syndrome, and others. We also compared and analyzed hematologic laboratory results, serum iron concentration, the presence of autoimmune antibodies, and thyroid function tests.

## Statistical analysis

The results are expressed as mean ± standard deviation. Pearson’s chi-square test and Fisher’s exact test were used to compare the sex ratio, nail changes, family history, and comorbidities, including autoimmune diseases, between the mild-to-moderate and severe AA groups. Comparison of age of onset, disease duration, and hematologic results between the two groups were performed using the independent t-test, and risk factors for severe AA were determined by logistic regression analysis. The analysis was performed using PASW Statistics ver. 18.0 (IBM Co., Armonk, NY, USA). A p-value < 0.05 was considered statistically significant.

## RESULTS

### General characteristics

A total of 1,137 individuals with AA were included: 583 male and 554 female. Average age was 32.63 ± 17.40 years and average duration was 19.86 ± 43.83 months. Mild-to-moderate AA was present in 883 patients (77.7%) and severe AA in 254 patients (22.3%) (Table 1). The average of onset was 30.77 ± 17.66 years and 30.60 ± 16.75 years in the mild-to-moderate and severe groups, respectively, and average disease duration was 15.89 ± 34.70 months and 33.68 ± 64.66 months, respectively. Duration was longer in the severe AA group than in the mild-to-moderate AA group (p < 0.001). The male-to-female ratio was 429:454 in the mild-to-moderate group and 154:100 in the severe group; thus male patients had more severe disease (p = 0.001). Family history and early onset (AA before 13 years old) were not significantly different between the two groups, but nail changes were more common in the severe group (p < 0.001, Table 2).

### Comorbidities

There was no significant difference in the frequencies of hypertension (p = 0.982), diabetes mellitus (p = 0.732), dyslipidemia (p = 0.160), atopic dermatitis (p = 0.849), or vitiligo (p = 0.129) between the two groups. Thyroid dis-

---

Table 1. Patient demographics and clinical data of the whole cohort (n = 1,137)

| Variable                      | Value               |
|-------------------------------|---------------------|
| Number of patients (male:female) | 583:554             |
| Mean age (yr)                 | 32.63 ± 17.40       |
| Duration (mo)                 | 19.86 ± 43.83       |
| Onset age (yr)                | 30.73 ± 17.45       |
| Family history                | 166 (14.6)          |
| Nail change                   | 59 (5.2)            |
| Severity*                     |                     |
| Mild-to-moderate              | 883 (77.7)          |
| Severe                        | 254 (22.3)          |
| Comorbid condition            |                     |
| Hypertension                  | 63 (5.5)            |
| Diabetes mellitus             | 28 (2.5)            |
| Dyslipidemia                  | 19 (1.7)            |
| Atopic dermatitis             | 60 (5.3)            |
| Vitiligo                      | 10 (0.9)            |
| Thyroid disease               | 84 (7.4)            |
| Autoimmune disease            | 109 (9.6)           |

Values are presented as number only, mean ± standard deviation, or number (%). *The patients with alopecia areata (AA) were subdivided into two groups according to scalp involvement; Mild-to-moderate AA: <50% of extent, severe AA: ≥50% of extent.
A Retrospective Study of 1,137 Korean Patients

Table 2. Characteristics of patients with AA according to severity

| Characteristic                      | Mild-to-moderate AA (n = 883) | Severe AA (n = 254) | p-value   |
|-------------------------------------|-------------------------------|---------------------|----------|
| Sex (male:female)†                  | 429:454                       | 154:100             | 0.001*   |
| Mean age (yr)                       | 32.31±17.65                   | 33.73±16.50         | 0.242†   |
| Duration (mo)                       | 15.89±34.70                   | 33.68±64.66         | <0.001†  |
| ≥12                                 | 242 (27.4)                    | 125 (49.2)          | <0.001*  |
| <12                                 | 641 (72.6)                    | 129 (50.8)          |          |
| Onset age (yr) of the patients      | 30.77±17.66                   | 30.60±16.75         | 0.893†   |
| Early onset‡                        |                               |                     |          |
| Onset before 13 years old           | 188 (21.3)                    | 48 (18.9)           | 0.401    |
| Family history‡                     | 130 (14.7)                    | 36 (14.2)           | 0.827    |
| Nail change‡                        | 28 (3.2)                      | 31 (12.2)           | <0.001*  |
| Comorbid condition†                 |                               |                     |          |
| Hypertension                        | 49 (5.5)                      | 14 (5.5)            | 0.982    |
| Diabetes mellitus                   | 21 (2.4)                      | 7 (2.8)             | 0.732    |
| Dyslipidemia                        | 12 (1.4)                      | 7 (2.8)             | 0.160    |
| Atopic dermatitis                   | 46 (5.2)                      | 14 (5.5)            | 0.849    |
| Vitiligo                            | 10 (1.1)                      | 0 (0)               | 0.129    |
| Thyroid disease                     | 54 (6.1)                      | 30 (11.8)           | 0.002*   |
| Autoimmune disease                  | 76 (8.6)                      | 33 (13.0)           | 0.036*   |

Values are presented as number only, mean±standard deviation, or number (%). AA: alopecia areata. *p-value <0.05 was considered statistically significant. †Independent samples t-test was used. ‡Chi-square test or Fishers exact test was used.

Table 3. Laboratory findings and autoantibodies in patients with AA

| Characteristic                      | Mild-to-moderate AA (n = 639) | Severe AA (n = 214) | p-value† |
|-------------------------------------|-------------------------------|---------------------|----------|
| Hgb (12 ~ 18 g/dl)                  | 14.09±4.28                    | 14.35±1.40          | 0.380    |
| WBC (4,800 ~ 10,600/mm³)            | 7,145.92±2,219.85             | 7,308.88±2,227.94   | 0.354    |
| Plt (130 K ~ 450 K/mm³)             | 262.88 K±85.38                | 260.78 K±66.25      | 0.743    |
| ALP (35 ~ 129 U/L)                  | 107.51±89.83                  | 93.37±64.52         | 0.028*   |
| AST (8 ~ 20 U/L)                    | 24.82±13.38                   | 23.39±9.43          | 0.169    |
| ALT (10 ~ 37 U/L)                   | 23.23±18.52                   | 21.89±13.40         | 0.280    |
| BUN (8 ~ 23 mg/dl)                  | 13.91±7.74                    | 13.48±3.49          | 0.500    |
| Cr (0.5 ~ 1.3 mg/dl)                | 0.79±0.94                     | 0.77±0.22           | 0.813    |
| Serum iron test                     |                               |                     |          |
| Serum iron (60 ~ 170 μg/dl)         | 94.23±4.13                    | 101.16±42.51        | 0.066    |
| TIBC (240 ~ 450 μg/dl)              | 328.59±51.28                  | 322.31±49.80        | 0.181    |
| Ferritin (4.63 ~ 274.60 ng/ml)      | 69.57±63.35                   | 78.83±72.73         | 0.138    |
| Transferrin (200 ~ 360 mg/dl)       | 262.78±49.26                  | 252.81±47.78        | 0.082    |
| Thyroid function test               |                               |                     |          |
| T3 (80 ~ 200 ng/dl)                 | 122.77±45.86                  | 122.53±32.00        | 0.953    |
| Free T4 (0.7 ~ 2.0 ng/dl)           | 1.30±0.34                     | 1.32±0.36           | 0.483    |
| TSH (0.4 ~ 4.5 μU/ml)               | 2.28±2.57                     | 2.51±4.85           | 0.476    |
| The presence of autoantibody        |                               |                     |          |
| ANA (present/absent)                | 80/480 (16.7)                 | 20/171 (11.7)       | 0.122†   |
| Antithyroglobulin antibody (present/absent) | 34/216 (15.7) | 14/92 (15.2) | 0.908†   |

Values are presented as mean±standard deviation or number (%). AA: alopecia areata, Hgb: hemoglobin, WBC: white blood cells, Plt: platelets, ALP: alkaline phosphatase, AST: aspartate transaminase, ALT: alanine transaminase, BUN: blood urea nitrogen, Cr: creatinine, TIBC: total iron binding capacity, TSH: thyroid-stimulating hormone, ANA: antinuclear antibody. *p-value <0.05 was considered statistically significant. †Independent samples t-test was used. **Chi-square test or Fishers exact test was used.

Laboratory results

Of the 1,137 total patients, 853 patients had laboratory blood test results: 639 in the mild-to-moderate group and...
214 in the severe group. The level of alkaline phosphatase (ALP) was lower in the severe group ($p = 0.028$). All other results, including serum iron and thyroid function, were not significantly different between groups (Table 3). Anti-nuclear antibody (ANA) was positive in 16.7% of the mild-to-moderate group and 11.7% of the severe group. Antithyroglobulin antibody was positive in 15.7% and 15.2% of the mild-to-moderate and severe groups, respectively (Table 3).

### Analysis of risk factors

To determine the risk factors of severe AA, the statistically significant factors of severe AA were analyzed by logistic regression analysis (Table 4). In multivariable logistic regression analysis, male sex ($p < 0.001$; odds ratio [OR], 1.726; 95% confidence interval [CI], 1.282–2.325), presence of nail changes ($p < 0.001$; OR, 4.104; 95% CI, 2.357–7.146), and disease duration greater than 1 year ($p < 0.001$; OR, 2.405; 95% CI, 1.791–3.229) were associated with an increased risk of severe AA (Table 4).

### DISCUSSION

AA presents with variable-sized, demarcated, oval or round patches of hair loss; the estimated lifetime risk among the general population is 1.7%.

Disease severity can be classified as follows: S1 ($< 25\%$ scalp involvement), S2 ($26\%–50\%$), S3 ($51\%–75\%$), S4 ($76\%–99\%$), and S5 ($100\%$, alopecia totalis) based on guidelines of the American National Alopecia Areata Foundation. However, owing to the variable size of lesions and the waxing and waning property of alopecia patches, several publications concerning treatment divide AA patients into two groups: mild-to-moderate (less than 50% scalp involvement; localized) and severe (greater than 50% scalp involvement; extensive). Severity of AA at the time of treatment initiation is known to be the most important prognostic factor, as reported by several other authors.

Hence, we compared the clinical profiles of mild-to-moderate and severe AA patient groups at first medical examination to investigate risk factors associated with severe AA.

Mean age of onset was similar between groups, but male sex was more common in the severe group ($p = 0.001$). Studies in India and China found that males had more severe AA, while female patients were more likely to have severe disease in a report from Singapore. The association of sex with AA severity is unclear, and additional study is needed.

According to previous reports, prognosis and treatment response is poor in patients with severe AA (particularly in cases of alopecia totalis and alopecia universalis), nail changes, a history of atopic dermatitis or other autoimmune disease, and longer period from symptom development to start of treatment initiation.

Our data shows that family history and early age of onset was not significantly different between the two groups. On the other hand, longer disease duration ($p < 0.001$) and nail changes ($p < 0.001$) were more common in severe AA. Early onset AA is alopecia that develops before adolescence. Disease severity and symptom development before 13 years of age had no significant association in our study ($p = 0.401$). $p$-values for the association of AA severity and age of onset were 0.305 before 10 years of age, 0.055 before 9 years, 0.055 before 8 years, 0.099 before 7 years, and 0.256 before 6 years. These results are quite different from those reported by previous studies.

Nail changes in AA can present as trachonychia, pitted nail, or longitudinal ridges; the frequency of nail changes increases with disease severity. We did not subdivide patients based on nail changes, but nail changes were more frequent in the severe AA group ($p < 0.001$). This is thought to be due to the action of inflammatory cells targeting hair follicles acting on nails, as their growth structure resembles that of hair follicles.

Disease duration was 15.89 ± 34.70 months and 33.68 ± 64.66 months in the mild-to-moderate and severe groups, respectively; thus the severe group showed disease duration twice that of the mild-to-moderate group.

### Table 4. Risk factors for severe alopecia areata

| Characteristic                      | Univariable analysis | Multivariable analysis |
|------------------------------------|----------------------|------------------------|
|                                    | OR       | 95% CI              | $p$-value | OR       | 95% CI              | $p$-value |
| Sex (male/female)                  | 1.637    | 1.232–2.175         | $<0.001^*$ | 1.726    | 1.282–2.325         | $<0.001^*$ |
| Nail change (present/absent)       | 4.245    | 2.494–7.225         | $<0.001^*$ | 4.104    | 2.357–7.146         | $<0.001^*$ |
| Thyroid disease (present/absent)   | 2.056    | 1.285–3.290         | 0.003*    | 3.501    | 0.943–13.001        | 0.061     |
| Autoimmune disease (present/absent)| 1.586    | 1.026–2.449         | 0.038*    | 0.604    | 0.176–2.007         | 0.423     |
| Duration ($\geq 1$ year/$< 1$ year)| 2.567    | 1.926–3.420         | $<0.001^*$ | 2.405    | 1.791–3.229         | $<0.001^*$ |

OR: odds ratio, 95% CI: 95% confidence interval. $^*$ $p$-value $< 0.05$ was considered statistically significant.
(p<0.001). The mild-to-moderate and severe AA groups had disease duration of greater than 1 year in 27.4% and 49.2% of patients (p<0.001). This finding is consistent with previous reports that prognosis is improved with early treatment initiation14,21.

The associations between AA and atopic dermatitis, vitiligo, autoimmune diseases, and thyroid diseases are well known4,5. However, we found no association between severity and atopic dermatitis (p=0.849). In the present investigation, 9.6% of patients had autoimmune disease. Thyroid diseases (p=0.002) were associated with severe AA, but vitiligo (p=0.129) was not. Additionally, autoimmune diseases were more common in the severe group (p=0.036). Based on these results, despite the unclear etiology of AA, an immune pathogenesis seems to play an important role22-24. Normal anagen hair is an immune privileged site. However, the loss of immune privilege allows for the progression of the inflammatory process, with infiltration of CD4+ and CD8+ T cells in AA24.

Although they were in normal range, ALP was significantly lower in the severe group (p=0.028). ALP is a zinc-metallo enzyme that is highly expressed in actively proliferating cells or cells with a high metabolic rate25. By immunohistochemical staining, ALP activity is prominent in normal pilosebaceous units, and there are several reports of decreased ALP activities in hair follicles of patients with AA and mouse models of AA25-27. ALP concentration in hair follicles can correlate with serum levels, and it is speculated that decreased serum ALP is due to diminished functioning follicles in chronic, severe AA.

On the other hand, iron levels and thyroid function test results were not significantly different between groups. Although there is controversy concerning the association of iron deficiency and AA28, our result is in agreement with previous research showing no correlation between iron deficiency and disease severity29-30. In our study, ANA was positive in 16.7% of patients in the mild-to-moderate group and 11.7% of patients in the severe group. Antithyroglobulin antibody was positive in 15.7% and 15.2%, respectively, with no statistically significant difference.

In logistic regression analysis, risk factors associated with increased disease severity were male sex (p<0.001), nail changes (p<0.001), and disease duration greater than 1 year (p<0.001). These results are similar to previous reports concerning AA prognosis. However, additional nationwide, ethnic studies should be performed in order to further investigate the correlation between sex and disease severity and to determine differences in other countries. This study is limited because it is a retrospective, single-center study based on review of patients’ medical record. Thus, the data is subject to recall bias. Since blood tests were not performed on all patients, it is difficult to generalize and interpret the data carefully. In addition, we only evaluated for the presence or absence of thyroid disease, and did not classify the diagnoses in details. Since we evaluated for the presence of ANA and antithyroglobulin antibody only, there is a possibility that the combined effects of multiple different autoimmune antibodies are underestimated. Additionally, we compared only the clinical profiles between two severity groups but we did not analyze the effect of different treatment modalities or prognostic factors.

Despite these limitations, this is the study on the largest scale of Korean patients with AA thus far. In conclusion, this study analyzed clinical profiles of patients with AA according to severity and evaluated risk factors associated with severe AA. We found that male sex, nail changes, and duration greater than 1 year are risk factors for severe disease. Other demographic and clinical parameters, such as a history of atopic dermatitis, vitiligo, and early AA onset were not associated with disease severity. Serum ALP level was significantly lower in the severe AA group, and represents a potentially useful predictor of prognosis and treatment response. However, further long-term and prospective studies are needed to clarify these issues.

CONFLICTS OF INTEREST

The authors have nothing to disclose.

REFERENCES

1. Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update: part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol 2010;62:177-188.
2. Assouly P, Reygagne P, Jouanique C, Matard B, Marechal E, Reynert P, et al. Intravenous pulse methylprednisolone therapy for severe alopecia areata: an open study of 66 patients. Ann Dermatol Venereol 2003;130:326-330.
3. Gilhar A, Etzioni A, Paus R. Alopecia areata. N Engl J Med 2012;366:1515-1525.
4. Kakourou T, Karachristou K, Chrousos G. A case series of alopecia areata in children: impact of personal and family history of stress and autoimmunity. J Eur Acad Dermatol Venereol 2007;21:356-359.
5. Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY, et al. Comorbidity profiles among patients with alopecia areata: the importance of onset age, a nationwide population-based study. J Am Acad Dermatol 2011;65:949-956.
6. Friedmann PS. Alopecia areata and autoimmunity. Br J Dermatol 1981;105:153-157.
7. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995;70:
8. Olsen E, Hordinsky M, McDonald-Hull S, Price V, Roberts J, Shapiro J, et al. Alopecia areata investigational assessment guidelines. National Alopecia Areata Foundation. J Am Acad Dermatol 1999;40:242-246.
9. Tosti A, Bellavista S, Iorizzo M. Alopecia areata: a long-term follow-up study of 191 patients. J Am Acad Dermatol 2006;55:438-441.
10. van der Steen PH, van Baar HM, Happle R, Boezeman JB, Perret CM. Prognostic factors in the treatment of alopecia areata with diphenyldicycloprenone. J Am Acad Dermatol 1991;24:227-230.
11. Sharma VK, Dawn G, Kumar B. Profile of alopecia areata in Northern India. Int J Dermatol 1996;35:22-27.
12. Xiao FL, Yang S, Liu JB, He PP, Yang J, Cui Y, et al. The epidemiology of childhood alopecia areata in China: a study of 226 patients. Pediatr Dermatol 2006;23:13-18.
13. Tan E, Tay YK, Giam YC. A clinical study of childhood alopecia areata in Singapore. Pediatr Dermatol 2002;19:298-301.
14. Park MS, Piao YJ, Park YO, Soo YJ, Suhr KB, Lee JH, et al. Analysis of the prognostic factors of alopecia areata. Korean J Dermatol 2004;42:825-832.
15. Tan E, Tay YK, Goh CL, Chin Giam Y. The pattern and profile of alopecia areata in Singapore—a study of 219 Asians. Int J Dermatol 2002;41:748-753.
16. De Waard-van der Spek FB, Oranje AP, De Raeymaecker DM, Peereboom-Wynia JD. Juvenile versus maturity-onset alopecia areata—a comparative retrospective clinical study. Clin Exp Dermatol 1989;14:429-433.
17. Lee NR, Kim BK, Yoon NY, Lee SY, Ahn SY, Lee WS. Differences in comorbidity profiles between early-onset and late-onset alopecia areata patients: a retrospective study of 871 Korean patients. Ann Dermatol 2014;26:722-726.
18. Muller SA, Winkelmann RK. Alopecia areata. An evaluation of 736 patients. Arch Dermatol 1963;88:290-297.
19. Sharma VK, Dawn G, Muralidhar S, Kumar B. Nail changes in 1000 Indian patients with alopecia areata. J Eur Acad Dermatol Venereol 1998;10:189-191.
20. Mustonen T, Pisp A, Mikkola ML, Pummila M, Kangas AT, Pakkasjärvi L, et al. Stimulation of ectodermal organ development by Ectodysplasian-A1. Dev Biol 2003;259:123-136.
21. Yang CC, Lee CT, Hsu CK, Lee YP, Wong TW, Chao SC, et al. Early intervention with high-dose steroid pulse therapy prolongs disease-free interval of severe alopecia areata: a retrospective study. Ann Dermatol 2013;25:471-474.
22. Bertolini M, Gilhar A, Paus R. Alopecia areata as a model for T cell-dependent autoimmune diseases. Exp Dermatol 2012;21:477-479.
23. Alexis AF, Dudda-Subramanya R, Sinha AA. Alopecia areata: autoimmune basis of hair loss. Eur J Dermatol 2004;14:364-370.
24. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest 2007;117:2019-2027.
25. Hahnel AC, Rappolee DA, Millan JL, Manes T, Ziemek CA, Theodosiou NG, et al. Two alkaline phosphatase genes are expressed during early development in the mouse embryo. Development 1990;110:555-564.
26. Li I, Paus R, Slominski A, Hoffman RM. Skin histoculture assay for studying the hair cycle. In Vitro Cell Dev Biol 1992;28:695-698.
27. Manes T, Glade K, Ziemek CA, Millán JL. Genomic structure and comparison of mouse tissue-specific alkaline phosphatase genes. Genomics 1990;8:541-554.
28. White MI, Currie J, Williams MP. A study of the tissue iron status of patients with alopecia areata. Br J Dermatol 1994;130:261-263.
29. Boffa MJ, Wood P, Griffiths CE. Iron status of patients with alopecia areata. Br J Dermatol 1995;132:662-664.
30. Gonul M, Cakmak SK, Soylu S, Kilic A, Gul U. Serum vitamin B12, folate, ferritin, and iron levels in Turkish patients with alopecia areata. Indian J Dermatol Venereol Leprol 2009;75:552.